Previous studies suggested that chordoma cells exhibiting a loss of CDKN2A (p16) may trigger universal activation of CDK4/6, implying the potential applicability of CDK4/6 inhibitor in chordoma treatment (Liu et al. 2018) (Passeri et al. 2022). This evidence concerns the gene CDK4 and chordoma.